For oncology diagnostics, Italy is the logical first market in Europe
CE-IVDR changed the rules. Italy's IRCCS network, aging demographics, and clinical research culture make it the strategic first step into Europe for cancer diagnostic companies.
Updated April 19, 2026
When diagnostics companies outside Europe begin planning their entry into the EU market, they rarely choose Italy first. The instinct is to start where the infrastructure is familiar - Ireland for its English-language environment, Germany for the size of its hospital market, the Netherlands for its regulatory proximity to Notified Bodies. Italy, in this mental hierarchy, comes later: a large market, certainly, but a complicated one. Something to tackle once the European operation is established.
This sequencing is understandable. It is also, for a specific and growing category of diagnostics companies, strategically wrong.
For companies developing oncology diagnostics - liquid biopsy panels, next-generation sequencing assays, companion diagnostics, early detection tests for age-correlated cancers - Italy offers a combination of clinical, regulatory, and commercial advantages that no other European market replicates.
The argument is not sentimental. It is built on three structural realities that are reshaping the economics of European market entry under the new CE-IVDR framework.
See also: CE-IVDR: what it means for your diagnostics market entry strategy
Three structural realities
The regulation changed the calculus
Clinical evidence generation is the true bottleneck in the CE-IVDR pathway - not the technical file, not the QMS, not even the Notified Body queue.
For Class C oncology diagnostics, CE-IVDR requires designing and executing studies in real clinical settings, with real patient populations, that produce data meeting Notified Body standards. The company that can do this efficiently gains a structural time advantage measurable in months, sometimes years.
51 hospitals most international companies have never heard of
Italy's IRCCS institutions are simultaneously treating centres and research hubs - carrying the patient volumes of major public hospitals with the research infrastructure of academic medical centres.
These institutions have established frameworks for industry collaboration, ethics committee processes familiar with device validation studies, and biobank infrastructure that supports sample collection at CE-IVDR scale. A well-prepared company working with the right IRCCS partner can access the patient populations, the research infrastructure, and the investigator expertise needed to design a clinical validation study around real clinical practice.
The demographic argument, stated precisely
Italy's median age - among the highest globally - is not merely a future commercial opportunity. For diagnostics targeting age-correlated oncological conditions, it is a present regulatory resource.
CE-IVDR requires clinical evidence generated in populations representative of the intended use. For age-correlated cancers, Italy's patient population is concentrated, accessible, and managed in research-grade settings - a materially different proposition from countries where patients are dispersed or institutional infrastructure less developed.
Like what you're reading?
Subscribe for more strategic notes on biotech and venture design.
CE-IVDR: from self-declaration to clinical proof
The transition to CE-IVDR introduced a requirement that most non-European companies initially underestimate: the obligation to generate clinical evidence that is scientifically valid, representative of the intended patient population, and sufficient to support the claimed performance of the device.
This is not a documentation exercise. For a Class C oncology diagnostic - which covers the majority of cancer-related IVDs, including most molecular panels and liquid biopsy assays - the clinical evidence requirement means designing and executing studies in real clinical settings, with real patient populations, that produce data meeting the standards of a Notified Body review.
Companies that have navigated FDA clearance processes are accustomed to analytical validation and limited clinical bridging studies. CE-IVDR asks for something more systematic, more prospective in its design, and more demanding in its statistical rigour.
The IRCCS advantage
Italy operates a network of over 50 IRCCS - Istituti di Ricovero e Cura a Carattere Scientifico, or scientific research hospitals - that occupy a unique position in the European clinical landscape. They are simultaneously treating institutions and research centres, funded partly by the national health service and partly by the Ministry of Health on the basis of their scientific output.
Patient access
Patient populations in Italian IRCCS oncology units are large, well-characterised, and accessible. Italy has one of the oldest populations in the world - meaning the disease burden in age-correlated cancers is concentrated in institutions that have been studying it systematically for decades.
Structured for partnership
The IRCCS system has established frameworks for industry collaboration. Following the 2023-2024 reform of Italy's ethics committee system into 40 Comitati Etici Territoriali (CET) and 3 Comitati Etici Nazionali (CEN), approval processes are more standardised, though operational variability between committees persists. Some IRCCS also maintain biobank infrastructure relevant to clinical evidence generation, though capability varies significantly across the network.
A note on data quality
One important caveat: not all data generated in IRCCS research settings will meet the quality, traceability, and documentation requirements that a Notified Body expects for a CE-IVDR submission. Studies intended to generate primary clinical evidence must be designed from the outset as formal Clinical Performance Studies under controlled conditions, not as standard academic research projects. The distinction between scientifically rigorous and regulatorily compliant is real, and it must be addressed before the first sample is processed.
The clinical evidence that emerges from this process does more than satisfy a regulatory requirement. It builds relationships with investigators who will become early advocates for the product, generates publications in the relevant clinical community, and creates familiarity with the product in institutions that will later become customers. These are strategic assets that a purely regulatory approach to market entry does not produce.
The core strategic logic
Designing a clinical validation study for a lung cancer liquid biopsy panel in a country where the relevant patient population is concentrated, accessible, and already being managed in research-grade clinical settings is a materially different proposition from designing the same study in a market where the patients are dispersed, the institutional infrastructure is less developed, or the research culture around industry partnership is less mature.
This sequencing converts a cost centre (clinical evidence generation) into a strategic investment: the same process that generates regulatory evidence also builds clinical relationships, produces publications, and establishes credibility with Italian oncologists. The regulatory and commercial preparation happen in parallel, not because they are the same activity, but because they draw on the same institutional partnerships.
What Italy is not
An honest argument requires stating what Italy does not offer, or does not offer easily.
Challenges to navigate with local expertise
Reimbursement complexity: A CE mark does not translate automatically into market access. The SSN reimburses through a combination of national procedures and regional formulary decisions, introducing heterogeneity that surprises companies accustomed to centralised health systems.
Procurement cycles: Institutional decision-making involves relationship-building processes that Anglo-American commercial cultures find frustrating.
Linguistic barriers: Less significant in research and regulatory contexts than in purely commercial ones, but real.
These are not arguments against Italy. They are arguments for entering Italy with local expertise rather than without it. A company that enters Italy with the right local expertise, that has relationships with the right IRCCS clinical partners, and that understands the regional dynamics will navigate these challenges efficiently. A company that discovers them after launch will not.
The right question to ask
The standard question
"Where is the largest market, and how do we access it?"
That leads to Germany.
The more useful question
"Where can we generate clinical evidence efficiently, in a representative population, while simultaneously building clinical relationships that drive adoption?"
That leads to Italy.
Italy is not a compromise, and not a secondary consideration. It is the logical first step in a European strategy built around the regulatory reality rather than against it.
Frequently asked questions
Navigating Europe's clinical and healthcare architecture requires strategic precision. Let's map the optimal route for your clinical validation and market entry.
Map your market entry